<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Puerarin, a major <z:chebi fb="0" ids="50753">isoflavonoid</z:chebi> derived from the Chinese medical herb Radix puerariae (kudzu root), has been reported to be useful in the treatment of various <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular diseases</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In the present study, we examined the detailed mechanisms underlying the inhibitory effects of puerarin on inflammatory and apoptotic responses induced by middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) in rats </plain></SENT>
<SENT sid="2" pm="."><plain>Treatment of puerarin (25 and 50 mg/kg; intraperitoneally) 10 min before MCAO dose-dependently attenuated focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in rats </plain></SENT>
<SENT sid="3" pm="."><plain>Administration of puerarin at 50 mg/kg, showed marked reduction in <z:mpath ids='MPATH_124'>infarct</z:mpath> size compared with that of control rats </plain></SENT>
<SENT sid="4" pm="."><plain>MCAO-induced focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> was associated with increases in <z:mp ids='MP_0005039'>hypoxia</z:mp>-inducible factor-1alpha (HIF-1alpha), inducible nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthase (iNOS), and active caspase-3 protein expressions as well as the <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-alpha (TNF-alpha) in ischemic regions </plain></SENT>
<SENT sid="5" pm="."><plain>These expressions were markedly inhibited by the treatment of puerarin (50 mg/kg) </plain></SENT>
<SENT sid="6" pm="."><plain>In addition, puerarin (10-50 microM) concentration-dependently inhibited respiratory bursts in human neutrophils stimulated by formyl-Met-Leu-Phe </plain></SENT>
<SENT sid="7" pm="."><plain>On the other hand, puerarin (20-500 microM) did not significantly inhibit the <z:chebi fb="0" ids="33202">thiobarbituric acid</z:chebi>-reactive substance reaction in rat brain homogenates </plain></SENT>
<SENT sid="8" pm="."><plain>An electron spin resonance (ESR) method was conducted on the scavenging activity of puerarin on the free radicals formed </plain></SENT>
<SENT sid="9" pm="."><plain>Puerarin (200 and 500 microM) did not reduce the ESR signal intensity of <z:chebi fb="1" ids="29191">hydroxyl radical</z:chebi> formation </plain></SENT>
<SENT sid="10" pm="."><plain>In conclusion, we demonstrate that puerarin is a potent neuroprotective agent on MCAO-induced focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in vivo </plain></SENT>
<SENT sid="11" pm="."><plain>This effect may be mediated, at least in part, by the inhibition of both HIF-1alpha and TNF-alpha activation, followed by the inhibition of <z:mp ids='MP_0001845'>inflammatory responses</z:mp> (i.e., iNOS expression), <z:mpath ids='MPATH_3'>apoptosis</z:mpath> formation (active caspase-3), and neutrophil activation, resulting in a reduction in the <z:mpath ids='MPATH_124'>infarct</z:mpath> volume in <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-reperfusion brain injury </plain></SENT>
<SENT sid="12" pm="."><plain>Thus, puerarin treatment may represent a novel approach to lowering the risk of or improving function in <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-reperfusion brain injury-related disorders </plain></SENT>
</text></document>